Brian Conley's questions to argenx SE (ARGX) leadership • Q1 2024
Question
Brian Conley, on behalf of Tom Smith, asked about efgartigimod's competitive positioning in thyroid eye disease (TED), any differentiating aspects of its Phase III trial design, and plans for chronic TED.
Answer
CEO Tim Van Hauwermeiren stated that the Phase III TED program is actively enrolling globally. He noted the trial design is similar to competitors but also includes a capped number of patients who have previously been treated with Tepezza. He also mentioned the study is utilizing the prefilled syringe but deferred further strategic details.